NASH, HCV cirrhosis predict coronary artery disease in liver transplantation

This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.

Patients who underwent liver transplantation evaluation had a high prevalence of coronary artery disease, especially those with nonalcoholic steatohepatitis-related cirrhosis, hepatitis C-related cirrhosis and alcoholic cirrhosis, according to a recently published study.

An integral component of the liver transplant evaluation (LTE) is coronary artery disease (CAD) assessment as surgical morbidity and mortality can be as high as 81% and 50%, respectively, in patients with significant CAD undergoing LT.

Type 2 diabetes, dyslipidemia, current or prior history of hypertension and NASH remained independent predictors of significant CAD (Coronary Artery Disease) after adjusting for age, sex, BMI and smoking and family history.

Read more…https://www.healio.com/hepatology/hepatitis-c/news/online/%7Bddeeb80d-e58a-4379-8452-bbcca1360554%7D/nash-hcv-cirrhosis-predict-coronary-artery-disease-in-liver-transplantation